Mark Boguniewicz

Affiliation: Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, USA

Mark Boguniewicz, M.D., is a Professor in the Division of Allergy-Immunology, Department of Pediatrics at National Jewish Medical and Research Center in Denver. He is also a Professor in the Department of Pediatrics at the University of Colorado Health Sciences Center and staff physician in the Department of Pediatrics at Children's Hospital in Denver. After completing his internship and residency in Pediatrics at Children's Hospital of Michigan and Fellowship in Allergy-Immunology and Rheumatology at Children's Hospital and Harvard Medical School in Boston, Massachusetts, he was an Instructor in Pediatrics at Harvard Medical School from 1988 - 1990. Dr. Boguniewicz joined the National Jewish medical staff in 1990.

Dr. Boguniewicz is Board Certified in both Pediatrics and Allergy-Immunology. He is a Fellow of the American Academy of Allergy, Asthma and Immumology, chair of the Dematologic Diseases Interest Section and chair of the Eczema Committee of the American Academy of Allergy, Asthma and Immumology. He is associate editor, Yearbook of Allergy, Asthma and Clinical Immunology. Dr. Boguniewicz's primary areas of clinical and research interest include allergy, immunology and asthma in children and atopic dermatitis in both children and adults. In collaboration with Dr. Donald Leung, his research focuses on immunopathogenesis and mechanisms of chronic inflammation in atopic dermatitis. Clinical trials include new treatments for atopic dermatitis in both children and adults and asthma and allergic rhinitis in children.

Selected Publications

1. Boguniewicz M. Conventional Topical Treatment of Atopic Dermatitis.In: Atopic Dermatitis, First Edition.Bieber T, Leung DYM (eds), Marcel Dekker (New York) 2001
   
2. Taha RA, Minshall EM, Leung DYM, Boguniewicz M, Luster A, Muro S, Toda M, Hamid QA. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis.J Allergy Clin Immunol 2000;105:1002-7
   
3. Boguniewicz M and Leung DYM. Allergic Diseases. In: Current Pediatric Diagnosis and Treatment, 15th Edition.Hay, Jr WW, Hayward AR, Levin MJ, Sondheimer JM (eds), Appleton and Lange (Stamford) 2000:939-964
   
4. Rosenwasser L, Boguniewicz M, Routes J, Milgrom H, Spahn JD (eds). Yearbook of Allergy, Asthma and Clinical Immunology. Mosby (St. Louis) 2000
   
5. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin J for the Pediatric Tacrolimus Study Group.A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102:637-644

Current Studies

1. Principal Investigator, Novartis Pharmaceuticals. A 26-week Study with a 6 Week Randomized, Multicenter, Double-blind, Vehicle-controlled, Parallel-group Phase Followed by a 20 Week Open-label Phase to Study the Safety and Efficacy of 1% ASM Cream in Pediatric Subjects with Atopic Dermatitis. 6/99-present.
2. Co-investigator, Fujisawa USA, Inc. An Open-Label Safety Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for the Treatment of Moderate or Severe Atopic Dermatitis. 7/99-present.
3. Principal Investigator, Forest Laboratories. A One-Year, Open-Label Study to Evaluate the Safety of HFA Flunisolide in Children with Mild to Moderate Asthma. 7/98-present.
4. Principal Investigator, Schering-Plough Research Institute. A One-Year, Open-Label Safety Study of Mometasone Furoate Dry Powder Inhaler (MF DPI) and Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength) in Children with Asthma Previously Maintained on Inhaled Corticosteroids. 4/98-present.
5. Investigator. Patch Testing in Chronic Beryllium Disease. B. Kotzin and L. Newman, Co-Principal Investigators, Pathogenic T Cells in Chronic Beryllium Disease, National Institute of Health RO1 9/98-present.
6. Sub-investigator. Role of Superantigens in Atopic Dermatitis. Principal Investigator, DYM Leung, M.D., Ph.D. Role of Bacterial Toxins in Human Skin Diseases. National Institute of Arthritis, Musculoskeletal and Skin Diseases grant 1 RO1 AR41256. 7/95-present.